Related Experiment Video
Updated: Mar 15, 2026

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
Published on: October 28, 2020
Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights
Sabrina Belaidi1,2,3, Mounira Kharoubi1,2,4,5,6,7, Olivier Lairez2,7,8
1French National Reference Centre for Cardiac Amyloidosis, Hospital Henri Mondor, Créteil, Île-de-France, France.
Insights
Cardiac amyloidosis (CA) presents across all ejection fraction phenotypes, not just preserved. Integrating LVEF, GLS, and CIx improves risk prediction for better patient management.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Amyloidosis Research
Background:
- Cardiac amyloidosis (CA) is increasingly recognized but often associated with heart failure with preserved ejection fraction (HFpEF).
- However, CA can manifest across the spectrum of left ventricular ejection fraction (LVEF), including mildly reduced (HFmrEF) and reduced (HFrEF) ejection fraction.
- Accurate recognition of CA across all LVEF phenotypes is crucial for timely diagnosis and effective risk stratification.
Purpose of the Study:
- To investigate the spectrum of LVEF phenotypes in cardiac amyloidosis.
- To evaluate the prognostic relevance of LVEF in conjunction with global longitudinal strain (GLS) and cardiac index (CIx).
- To develop a prognostic model integrating these parameters for improved risk stratification in CA patients.
Main Methods:
- A retrospective study of 2244 CA patients (light chain, hereditary transthyretin, wild-type transthyretin amyloidosis) was conducted.
- LVEF was classified per European Society of Cardiology guidelines.
- Prognostic value was assessed using Kaplan-Meier analysis and a decision tree combining LVEF, GLS, and CIx, with external validation.
Main Results:
- While HFpEF was most common, 39% of patients had HFmrEF or HFrEF.
- Survival varied significantly by phenotype: median survival was 30 months (HFrEF), 40 months (HFmrEF), and not reached (HFpEF).
- A decision tree integrating LVEF, GLS, and CIx identified four distinct prognostic groups with varying 4-year mortality risks.
Conclusions:
- Cardiac amyloidosis encompasses the full range of LVEF phenotypes.
- Combining LVEF, GLS, and CIx significantly enhances prognostic stratification in CA.
- A multimodal imaging approach is recommended for early diagnosis and personalized management of CA.
Background:
Although cardiac amyloidosis (CA) is often considered to be a cause of heart failure with preserved ejection fraction (HFpEF), many patients present with mildly reduced (HFmrEF) or reduced ejection fraction (HFrEF). Recognising CA across this spectrum is essential for diagnosis and risk stratification.
Methods:
We studied 2244 patients with CA (557 light chain amyloidosis, 392 hereditary transthyretin amyloidosis, 1137 wild-type transthyretin amyloidosis) at the French national reference centre. Left ventricular ejection fraction (LVEF) was classified according to European Society of Cardiology guidelines. We evaluated the prognostic relevance of LVEF and its interaction with global longitudinal strain (GLS) and cardiac index (CIx). Survival was assessed with a Kaplan-Meier analysis, and a decision tree combined LVEF, GLS and CIx. Our findings were confirmed externally in an independent, French validation cohort.
Results:
Although HFpEF was the most common phenotype, 39% of patients presented with HFmrEF or HFrEF. The survival time varied with the phenotype; the median was 30 months in HFrEF, 40 months in HFmrEF and was not reached in HFpEF. LVEF correlated moderately with GLS and weakly with CIx. A decision tree integrating LVEF, GLS and CIx identified four prognostic groups with HRs for 4-year mortality ranging from 1.6 to 3.7.
Conclusions:
CA affects the full spectrum of LVEF phenotypes. The integration of LVEF, GLS and CIx improves prognostic stratification and argues in favour of a multimodal imaging approach for early diagnosis and individualised management.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...

